Last reviewed · How we verify
UVADEX
Uvadex is a small molecule drug developed by the London Health Sciences Centre Research Institute or Lawson Research Institute of St. Joseph's. However, due to the lack of available information, its target, drug class, and approved indications are unknown. Uvadex is not FDA-approved, and its commercial status, generic manufacturers, and patent status are also unclear. As a result, there is limited information available on its safety profile and key considerations. Further research is needed to understand the properties and potential uses of Uvadex.
At a glance
| Generic name | UVADEX |
|---|---|
| Also known as | 8-mop |
| Sponsor | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Boxed warnings
- UVADEX ® (methoxsalen) Sterile Solution should be used only by physicians who have special competence in the diagnosis and treatment of cutaneous T-cell lymphoma and who have special training and experience in the THERAKOS ® CELLEX ® Photopheresis System. Please consult the CELLEX ® Operator's Manual before using this product.
Common side effects
- Hypotension
- Nausea
- Dysgeusia
- Photosensitivity reaction
- Pyrexia
- Rash
Serious adverse events
- Cardiovascular adverse experiences
- Arrhythmia
- Infection
- Hickman catheter infection
- Anaphylaxis
- Hypersensitivity reaction
Key clinical trials
- Impact of ExtraCorporeal Phototherapy (ECP) on Auxiliary Follicular T-lymphocytes and Circulating B-lymphocytes During Chronic AntiBody-Mediated Rejection in Kidney Transplantation. (NA)
- Single Patient Compassionate Use of X-PACT in Salvage Treatment of Prostate Cancer
- X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma (PHASE1)
- Extracorporeal Photopheresis in Sezary Syndrome
- EPIC- Extracorporeal Photopheresis (ECP) for Immune-related Colitis (PHASE2)
- Prevention of GVHD in Patients Treated With Allogeneic SCT: Possible Role of Extracorporeal Photophoresis (NA)
- Photopheresis in Early-stage Mycosis Fungoides (PHASE2)
- Photopheresis in GvHD After Hematopoietic Transplantation: Characteristics of the Procedure and of the Cell Product
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: